Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569139 | 0.88 | SMN1; SMN2 (0.46) | KMT2AMAPTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL5567966 | 0.86 | LMNA (0.42) | KMT2AHTTSMN1; SMN2MEN1 | |
| SCHEMBL5563864 | 0.84 | KDM4E (0.38) | KMT2AMAPTKDM4ESMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5569140 | 0.83 | KDM4E (0.38) | KMT2AMAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL5564164 | 0.82 | MAPT (0.44) | KMT2AMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL5569297 | 0.81 | BRD4 (0.44) | KMT2ABRD4 | |
| SCHEMBL5567835 | 0.79 | GAA (0.47) | KMT2AMAPTKDM4EHTTSMN1; SMN2 | |
| SCHEMBL27596194 | 0.79 | KDM4E (0.40) | MAPTKDM4EHTTSMN1; SMN2HPGD | |
| SCHEMBL5565141 | 0.79 | LMNA (0.45) | KMT2AATMSMN1; SMN2HPGDMEN1 | |
| SCHEMBL5563859 | 0.78 | PIK3CG (0.47) | KMT2AMAPTKDM4ESMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480976-B1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-19 | — | — | EP | disclosed |
| EP-1480976-A1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| US-6686381-B2 | COMPOUNDS THAT ANTAGONIZE NEUROPEPTIDE Y AT THE Y5 RECEPTOR SUBTYPE REPRESENT AN APPROACH TO THE TREATMENT OF EATING DISORDERS SUCH AS OBESITY AND HYPERPHAGIA | HOFFMANN-LA ROCHE INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030225141-A1 | THIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003072577-A1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225141-A1 | THIAZOLE DERIVATIVES | SLC5A1, GPR119, TAS1R1 | KMT2A 2916/4885MAPT 3615/4885KDM4E 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.